CUE
Closed
Cue Biopharma
0.6724
-0.0099 (-1.45%)
Last Update: 01 Jul 2025 23:25:00
Yesterday: 0.6823
Day's Range: 0.6512 - 0.69775
Send
sign up or login to leave a comment!
When Written:
3.57
Cue Biopharma is a clinical-stage biopharmaceutical company that is focused on developing a new class of medicines, called Immuno-STATs, which are designed to harness the power of the immune system to selectively target and destroy cancer cells. The company's proprietary technology platform, called the Cue Biologics Platform, combines computational biology, protein engineering, and synthetic chemistry to create Immuno-STATs that can be tailored to target specific cancer cells.
Cue Biopharma's lead product candidate, CUE-101, is currently in clinical trials for the treatment of HPV+ head and neck cancer. The company is also developing a pipeline of Immuno-STATs for the treatment of other types of cancer, including non-small cell lung cancer, melanoma, and colorectal cancer.
Cue Biopharma was founded in 2014 and is headquartered in Cambridge, Massachusetts. The company has partnerships with Merck and the National Cancer Institute, and has raised over $130 million in funding from investors including Johnson & Johnson Innovation, Fidelity Management & Research Company, and Decheng Capital.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Cue Biopharma's lead product candidate, CUE-101, is currently in clinical trials for the treatment of HPV+ head and neck cancer. The company is also developing a pipeline of Immuno-STATs for the treatment of other types of cancer, including non-small cell lung cancer, melanoma, and colorectal cancer.
Cue Biopharma was founded in 2014 and is headquartered in Cambridge, Massachusetts. The company has partnerships with Merck and the National Cancer Institute, and has raised over $130 million in funding from investors including Johnson & Johnson Innovation, Fidelity Management & Research Company, and Decheng Capital.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








